Mr. Rene Goehrum reports

BIOSYENT SCHEDULES Q2 AND H1 2026 EARNINGS RELEASE FOR AUGUST 20, 2026

BioSyent Inc. will release its consolidated financial results for the three and six months ended June 30, 2026, on Thursday, Aug. 13, 2026, after market hours. A presentation on the company's second quarter and first half 2026 results by Rene Goehrum, BioSyent president and chief executive officer, will also be available on the company's website on the date of release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty health care product company focused on acquiring or inlicensing, marketing, and distributing innovative pharmaceutical and oral health products that have been developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals that treat these patients by marketing its products through its pharmaceutical and oral health businesses, both in Canada and internationally.

As of the date of this press release, the company has 11,312,635 common shares outstanding.

We seek Safe Harbor.